 Sydney, Aug. 05, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy carboplatin and pemetrexed combined with Immuteps lead product candidate eftilagimod alpha efti or IMP321. 